KILR Bioassay Kits
Bioassay Kit Name |
Cancer Cell Type |
Target |
Assay Measures |
Drug Name |
Bioassay Kits & Configuration |
KILR Raji ADCC Bioassay Kit |
Burkitt’s lymphoma |
CD19, CD20, CD38 |
Antibody-Dependent Cellular-Cytotoxicity |
Rituximab |
97-1012Y026-00169 (2-plate)
97-1012Y026-00170 (10-plate) |
KILR Daudi ADCC Bioassay Kit |
Burkitt’s lymphoma |
CD19; CD20; CD38 |
Antibody-Dependent Cellular-Cytotoxicity |
Rituximab |
97-1009Y025-00171 (2-plate)
97-1009Y025-00172 (10-plate) |
KILR Raji ADCP Bioassay Kit |
Burkitt’s lymphoma |
CD19; CD20; CD38 |
Antibody-Dependent Cellular-Phagocytosis |
Rituximab |
97-1012Y026-00179 (2-plate)
97-1012Y026-00180 (10-plate) |
KILR Daudi ADCP Bioassay Kit |
Burkitt’s lymphoma |
CD19; CD20; CD38 |
Antibody-Dependent Cellular-Phagocytosis |
Rituximab |
97-1009Y025-00177 (2-plate)
97-1009Y025-00178 (10-plate) |
Request qualification data set for KILR® Raji ADCC Bioassay Kit using rituximab.
The KILR platform is based on the industry-validated Enzyme-Fragment Complementation (EFC) technology. EFC is based on two recombinant β-galactosidase (β-gal) enzyme fragments that act as an enzyme acceptor (EA) and an enzyme donor (ED). Separately, the fragments are inactive, but when combined, they form an active β-gal enzyme that hydrolyzes its substrate to produce a chemiluminescence signal.
Perform Potency Assays
Qualification data for KILR Raji Bioassay using rituximab demonstrating the assays ability to determine relative potencies. A. Study design for qualification of KILR Raji ADCC Bioassay. Five nominal concentrations of rituximab were evaluated over a range of 50% to 150%. Repeatability (4 runs) was assessed at the 100% nominal concentration by a single analyst. Intermediate precision incorporated several sources of variability, including multiple analysts, multiple days, 2 lots of KILR Raji Bioassay target cells, and 3 different lot of KILR CD16 Effectors. B. Results obtained from the qualification study indicate very good accuracy, high repeatability, intermediate precision, and dilutional linearity for KILR Raji Bioassay.